Vorasidenib

File:Vorasidenib v2.svg

Vorasidenib v2

Vorasidenib is an investigational drug that is being studied for its potential use in the treatment of certain types of cancer. It is a small molecule inhibitor that targets specific mutations in the isocitrate dehydrogenase (IDH) enzymes, particularly IDH1 and IDH2. These mutations are often found in various types of gliomas and other cancers.

Mechanism of Action

Vorasidenib works by inhibiting the mutant forms of the IDH1 and IDH2 enzymes. These mutations lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which can contribute to the development and progression of cancer. By inhibiting these mutant enzymes, vorasidenib reduces the levels of 2-HG, thereby potentially slowing down or stopping the growth of cancer cells.

Clinical Development

Vorasidenib is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are focused on patients with IDH1 or IDH2 mutant gliomas and other cancers. The drug has shown promise in early-phase trials, leading to further studies to confirm its benefits and determine the optimal dosing regimen.

Potential Indications

The primary focus of vorasidenib's development is for the treatment of gliomas, particularly those with IDH1 or IDH2 mutations. However, its mechanism of action suggests that it may also be effective in other cancers with similar mutations, such as certain types of acute myeloid leukemia (AML) and cholangiocarcinoma.

Side Effects

As an investigational drug, the full side effect profile of vorasidenib is not yet known. However, common side effects observed in clinical trials include fatigue, nausea, and elevated liver enzymes. More serious side effects are being closely monitored as the drug progresses through clinical development.

See Also

• Isocitrate dehydrogenase
• Glioma
• Acute myeloid leukemia
• Cholangiocarcinoma
• Cancer treatment

External Links

-